Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesityEli Lilly and Company has announced positive topline results from the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide...
Lilly's Zepbound (tirzepatide) achieved total mean weight loss of 26.0% from baseline to 88 weeksDetailed results from SURMOUNT-4 have shown Zepbound (tirzepatide) injection achieved superior mean percent change in body weight...
Novo Nordisk to initiate study assessing CagriSema vs TirzepatideNovo Nordisk is planning a study that will see CagriSema, a new investigational medicine developed by Novo that combines Cagrilintide and...
Once-daily oral nonpeptide GLP-1-RA achieved up to 14.7% mean weight reduction at 36 weeksPhase 2 data for orforglipron (12 mg, 24 mg, 36 mg or 45 mg), a nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, has...
SURMOUNT-1: Tirzepatide results in 22.5% weight loss in adults with obesity or overweightTirzepatide (5 mg, 10 mg, 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in topline results from Eli...
Standardisation of OAGB is key to reducing surgical errors and ensuring consistent patient outcomes12 hours ago